ArticleNeuroradiology2026
Paediatric thalamic tumours: a predictive MR phenotype.
Article in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo utilise MR phenotyping in accurately predicting paediatric thalamic tumour type via qualitative MR analysis and quantitative diffusion histogram analysis, with the aim of optimising pre-surgical planning and patient outcomes.
methodsPatients with tumours epicentred in the thalamus were identified through an electronic patient record search (2000 to 2024). Radiological features evaluated included tumour margins, homogeneity, cystic components, T1 and T2 signal, contrast enhancement, and haemorrhage. Histopathological tumour type, WHO grade, and molecular subtype were recorded. Tumour masks incorporating both solid and cystic components were manually drawn on T2-weighted b0 images and ADC histograms were constructed and analysed.
results34 patients (12 male, 22 female) were included, with a mean age of 10.4 years (range 2.4 months to 16 years). Diffuse midline gliomas (DMG) accounted for 24% and pilocytic astrocytomas (PA) for 28% of the cohort. Further tumour types included low-grade astrocytomas (9%), DNETs, PXAs, and embryonal tumours (8.8% each), with germinoma, glioblastoma, supratentorial ependymoma, ganglioglioma, lymphoma, and ATRT each comprising 3%. ADC p10 was significantly lower in DMG than PA (877 ± 152 vs. 1053 ± 152 × 10⁻⁶ mm²/s; t = 2.25, df = 13, p = 0.042, Cohen's d = 1.16). ADC mean showed a large but non-significant difference (p = 0.068). PAs were well-defined and microcystic with brush-like enhancement. DMGs were ill-defined with patchy enhancement, lower ADC values, and frequent susceptibility artefact.
conclusionDistinctive qualitative and quantitative MR features, particularly ADC p10, can guide the neuroradiologist in predicting tumour type and informing the decision between safe maximal resection and biopsy-first surgical pathways.
Indexed as
Identifiers
42873296What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.